BIOMAT Database Logo BIOMAT Database Logo

Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men. 1989

A U Decensi, and D Guarneri, and P Marroni, and L Di Cristina, and M Paganuzzi, and F Boccardo
Department of Clinical Oncology, National Institute for Cancer Research, Genoa, Italy.

Testicular responsiveness to 5,000 IU of human chorionic gonadotropin was evaluated in 14 patients with prostate cancer who were being treated with a slow-release luteinizing hormone-releasing hormone agonist for a median of 21 months. Serum testosterone response to human chorionic gonadotropin was markedly reduced in most patients, with the median level increasing from 0.25 to 1.65 nmol. per l. A second human chorionic gonadotropin test was repeated later in 5 patients who had been off treatment for a median of 6 months. Median serum testosterone levels increased to a maximum of 2.6 nmol. per l. compared to 28.2 nmol. per l. in an age-matched control group (p equals 0.008). Therefore, we conclude that long-term treatment with luteinizing hormone-releasing hormone agonists in elderly men leads to gonadal impairment that may not be as reversible as generally suggested.

UI MeSH Term Description Entries
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D007987 Gonadotropin-Releasing Hormone A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. FSH-Releasing Hormone,GnRH,Gonadoliberin,Gonadorelin,LH-FSH Releasing Hormone,LHRH,Luliberin,Luteinizing Hormone-Releasing Hormone,Cystorelin,Dirigestran,Factrel,Gn-RH,Gonadorelin Acetate,Gonadorelin Hydrochloride,Kryptocur,LFRH,LH-RH,LH-Releasing Hormone,LHFSH Releasing Hormone,LHFSHRH,FSH Releasing Hormone,Gonadotropin Releasing Hormone,LH FSH Releasing Hormone,LH Releasing Hormone,Luteinizing Hormone Releasing Hormone,Releasing Hormone, LHFSH
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D006063 Chorionic Gonadotropin A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN). Chorionic Gonadotropin, Human,HCG (Human Chorionic Gonadotropin),Biogonadil,Choriogonadotropin,Choriogonin,Chorulon,Gonabion,Human Chorionic Gonadotropin,Pregnyl,Gonadotropin, Chorionic,Gonadotropin, Human Chorionic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006908 Hydroxyprogesterones Metabolites or derivatives of PROGESTERONE with hydroxyl group substitution at various sites.
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A U Decensi, and D Guarneri, and P Marroni, and L Di Cristina, and M Paganuzzi, and F Boccardo
Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
August 1982, Fertility and sterility,
A U Decensi, and D Guarneri, and P Marroni, and L Di Cristina, and M Paganuzzi, and F Boccardo
Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty.
August 1988, The Journal of clinical endocrinology and metabolism,
A U Decensi, and D Guarneri, and P Marroni, and L Di Cristina, and M Paganuzzi, and F Boccardo
Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
March 2007, Asian journal of andrology,
A U Decensi, and D Guarneri, and P Marroni, and L Di Cristina, and M Paganuzzi, and F Boccardo
Testicular modulation of luteinizing hormone response to gonadotropin-releasing hormone (GnRH)-agonist treatment.
March 1987, Biology of reproduction,
A U Decensi, and D Guarneri, and P Marroni, and L Di Cristina, and M Paganuzzi, and F Boccardo
Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
March 2006, The Prostate,
A U Decensi, and D Guarneri, and P Marroni, and L Di Cristina, and M Paganuzzi, and F Boccardo
Testicular androgens in prostate cancer patients treated with a luteinizing hormone releasing hormone agonist.
May 1994, The Journal of urology,
A U Decensi, and D Guarneri, and P Marroni, and L Di Cristina, and M Paganuzzi, and F Boccardo
[Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
December 1990, Nihon Sanka Fujinka Gakkai zasshi,
A U Decensi, and D Guarneri, and P Marroni, and L Di Cristina, and M Paganuzzi, and F Boccardo
Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
June 2008, Urology,
A U Decensi, and D Guarneri, and P Marroni, and L Di Cristina, and M Paganuzzi, and F Boccardo
Long-term results of long-acting luteinizing-hormone-releasing hormone agonist in central precocious puberty.
January 1991, Hormone research,
A U Decensi, and D Guarneri, and P Marroni, and L Di Cristina, and M Paganuzzi, and F Boccardo
Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin.
June 1977, Biochemical and biophysical research communications,
Copied contents to your clipboard!